Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina.
Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Gastroenterology. 2020 Jan;158(1):67-75.e1. doi: 10.1053/j.gastro.2019.07.064. Epub 2019 Aug 31.
The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available evidence and expert recommendations regarding the clinical care of patients with pancreatic necrosis and to offer concise best practice advice for the optimal management of patients with this highly morbid condition.
This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. This review is framed around the 15 best practice advice points agreed upon by the authors, which reflect landmark and recent published articles in this field. This expert review also reflects the experiences of the authors, who are advanced endoscopists or hepatopancreatobiliary surgeons with extensive experience in managing and teaching others to care for patients with pancreatic necrosis. BEST PRACTICE ADVICE 1: Pancreatic necrosis is associated with substantial morbidity and mortality and optimal management requires a multidisciplinary approach, including gastroenterologists, surgeons, interventional radiologists, and specialists in critical care medicine, infectious disease, and nutrition. In situations where clinical expertise may be limited, consideration should be given to transferring patients with significant pancreatic necrosis to an appropriate tertiary-care center. BEST PRACTICE ADVICE 2: Antimicrobial therapy is best indicated for culture-proven infection in pancreatic necrosis or when infection is strongly suspected (ie, gas in the collection, bacteremia, sepsis, or clinical deterioration). Routine use of prophylactic antibiotics to prevent infection of sterile necrosis is not recommended. BEST PRACTICE ADVICE 3: When infected necrosis is suspected, broad-spectrum intravenous antibiotics with ability to penetrate pancreatic necrosis should be favored (eg, carbapenems, quinolones, and metronidazole). Routine use of antifungal agents is not recommended. Computed tomography-guided fine-needle aspiration for Gram stain and cultures is unnecessary in the majority of cases. BEST PRACTICE ADVICE 4: In patients with pancreatic necrosis, enteral feeding should be initiated early to decrease the risk of infected necrosis. A trial of oral nutrition is recommended immediately in patients in whom there is absence of nausea and vomiting and no signs of severe ileus or gastrointestinal luminal obstruction. When oral nutrition is not feasible, enteral nutrition by either nasogastric/duodenal or nasojejunal tube should be initiated as soon as possible. Total parenteral nutrition should be considered only in cases where oral or enteral feeds are not feasible or tolerated. BEST PRACTICE ADVICE 5: Drainage and/or debridement of pancreatic necrosis is indicated in patients with infected necrosis. Drainage and/or debridement may be required in patients with sterile pancreatic necrosis and persistent unwellness marked by abdominal pain, nausea, vomiting, and nutritional failure or with associated complications, including gastrointestinal luminal obstruction; biliary obstruction; recurrent acute pancreatitis; fistulas; or persistent systemic inflammatory response syndrome. BEST PRACTICE ADVICE 6: Pancreatic debridement should be avoided in the early, acute period (first 2 weeks), as it has been associated with increased morbidity and mortality. Debridement should be optimally delayed for 4 weeks and performed earlier only when there is an organized collection and a strong indication. BEST PRACTICE ADVICE 7: Percutaneous drainage and transmural endoscopic drainage are both appropriate first-line, nonsurgical approaches in managing patients with walled-off pancreatic necrosis (WON). Endoscopic therapy through transmural drainage of WON may be preferred, as it avoids the risk of forming a pancreatocutaneous fistula. BEST PRACTICE ADVICE 8: Percutaneous drainage of pancreatic necrosis should be considered in patients with infected or symptomatic necrotic collections in the early, acute period (<2 weeks), and in those with WON who are too ill to undergo endoscopic or surgical intervention. Percutaneous drainage should be strongly considered as an adjunct to endoscopic drainage for WON with deep extension into the paracolic gutters and pelvis or for salvage therapy after endoscopic or surgical debridement with residual necrosis burden. BEST PRACTICE ADVICE 9: Self-expanding metal stents in the form of lumen-apposing metal stents appear to be superior to plastic stents for endoscopic transmural drainage of necrosis. BEST PRACTICE ADVICE 10: The use of direct endoscopic necrosectomy should be reserved for those patients with limited necrosis who do not adequately respond to endoscopic transmural drainage using large-bore, self-expanding metal stents/lumen-apposing metal stents alone or plastic stents combined with irrigation. Direct endoscopic necrosectomy is a therapeutic option in patients with large amounts of infected necrosis, but should be performed at referral centers with the necessary endoscopic expertise and interventional radiology and surgical backup. BEST PRACTICE ADVICE 11: Minimally invasive operative approaches to the debridement of acute necrotizing pancreatitis are preferred to open surgical necrosectomy when possible, given lower morbidity. BEST PRACTICE ADVICE 12: Multiple minimally invasive surgical techniques are feasible and effective, including videoscopic-assisted retroperitoneal debridement, laparoscopic transgastric debridement, and open transgastric debridement. Selection of approach is best determined by pattern of disease, physiology of the patient, experience and expertise of the multidisciplinary team, and available resources. BEST PRACTICE ADVICE 13: Open operative debridement maintains a role in the modern management of acute necrotizing pancreatitis in cases not amenable to less invasive endoscopic and/or surgical procedures. BEST PRACTICE ADVICE 14: For patients with disconnected left pancreatic remnant after acute necrotizing mid-body necrosis, definitive surgical management with distal pancreatectomy should be undertaken in patients with reasonable operative candidacy. Insufficient evidence exists to support the management of the disconnected left pancreatic remnant with long-term transenteric endoscopic stenting. BEST PRACTICE ADVICE 15: A step-up approach consisting of percutaneous drainage or endoscopic transmural drainage using either plastic stents and irrigation or self-expanding metal stents/lumen-apposing metal stents alone, followed by direct endoscopic necrosectomy, and then surgical debridement is reasonable, although approaches may vary based on the available clinical expertise.
美国胃肠病学协会 (AGA) 研究所临床实践更新的目的是回顾有关胰腺坏死患者临床护理的现有证据和专家建议,并为这类病情严重的患者提供最佳管理的简明实用建议。
本专家综述由 AGA 研究所临床实践更新委员会和 AGA 理事会委托和批准,旨在为 AGA 成员提供对临床重要性高的主题的及时指导,并由临床实践更新委员会进行内部同行评议,通过胃肠病学的标准程序进行外部同行评议。本综述围绕作者达成的 15 个最佳实践建议点展开,这些建议点反映了该领域的里程碑和最近发表的文章。本综述还反映了作者的经验,作者是经验丰富的内镜医生或肝胆胰外科医生,在管理和指导他人治疗胰腺坏死患者方面拥有丰富的经验。
最佳实践建议 1:胰腺坏死与大量发病率和死亡率相关,最佳管理需要多学科方法,包括胃肠病学家、外科医生、介入放射科医生以及重症监护、传染病和营养方面的专家。在临床专业知识可能有限的情况下,应考虑将有大量胰腺坏死的患者转至适当的三级保健中心。
最佳实践建议 2:只有在培养出感染或强烈怀疑感染(即收集物中有气体、菌血症、败血症或临床恶化)的情况下,才应使用抗生素预防无菌性坏死感染。不建议常规使用预防性抗生素预防无菌性坏死感染。
最佳实践建议 3:当怀疑感染性坏死时,应首选能够穿透胰腺坏死的广谱静脉内抗生素(例如,碳青霉烯类、喹诺酮类和甲硝唑)。不建议常规使用抗真菌药物。在大多数情况下,不建议对胰腺坏死进行 CT 引导下的细针抽吸进行革兰氏染色和培养。
最佳实践建议 4:对于胰腺坏死患者,应尽早开始肠内喂养以降低感染性坏死的风险。对于无恶心和呕吐且无严重肠梗阻或胃肠道腔道梗阻迹象的患者,应立即尝试口服营养。如果无法口服营养,则应尽快通过鼻胃/十二指肠或鼻空肠管开始肠内营养。只有在无法或无法耐受口服或肠内喂养的情况下,才应考虑全胃肠外营养。
最佳实践建议 5:对于感染性坏死患者,需要引流和/或清创胰腺坏死。对于无菌性胰腺坏死且持续存在腹痛、恶心、呕吐和营养衰竭或伴有相关并发症(包括胃肠道腔道梗阻、胆道梗阻、复发性急性胰腺炎、瘘管或持续的全身炎症反应综合征)的患者,可能需要引流和/或清创。
最佳实践建议 6:应避免在早期、急性(头 2 周)进行胰腺清创术,因为它与增加的发病率和死亡率有关。只有在存在有组织的集合和强烈的指征时,才能最佳地延迟清创术并尽早进行。
最佳实践建议 7:经皮引流和经壁内镜引流都是治疗胰腺包裹性坏死 (WON) 的一线非手术方法。通过 WON 经壁引流进行内镜治疗可能更受欢迎,因为它避免了形成胰皮瘘的风险。
最佳实践建议 8:对于感染性或有症状的坏死性积聚的患者,应在早期、急性(<2 周)时考虑经皮引流,对于无法进行内镜或手术干预的 WON 患者也应考虑经皮引流。对于 WON 有深部延伸至结肠旁沟和骨盆的情况,或者对于内镜或手术清创后仍有残余坏死负担的情况,经皮引流应强烈考虑作为内镜引流的辅助治疗。
最佳实践建议 9:自膨式金属支架(例如腔镜贴合金属支架)似乎优于塑料支架用于坏死的内镜经壁引流。
最佳实践建议 10:只有那些单独使用大口径自膨式金属支架/腔镜贴合金属支架或联合冲洗的塑料支架不能充分缓解的有限坏死的患者,才应保留使用直接内镜坏死切除术。直接内镜坏死切除术是大量感染性坏死患者的一种治疗选择,但应在具有必要内镜专业知识和介入放射学及外科后备资源的转诊中心进行。
最佳实践建议 11:在可能的情况下,微创手术方法优于开放性外科坏死切除术,因为微创方法的发病率较低。
最佳实践建议 12:多种微创外科技术是可行且有效的,包括经皮辅助后腹腔镜清创术、腹腔镜经胃清创术和开放性经胃清创术。方法的选择最好根据疾病模式、患者生理机能、多学科团队的经验和专业知识以及可用资源来确定。
最佳实践建议 13:对于不符合微创内镜和/或手术程序适应证的急性坏死性胰腺炎患者,开放性手术清创术仍然发挥作用。
最佳实践建议 14:对于急性坏死性中体中部胰腺坏死后遗留的左胰腺残端断开的患者,如果有合理的手术适应证,应进行根治性手术治疗,即远端胰腺切除术。对于断开的左胰腺残端的管理,缺乏长期经肠内镜支架的证据支持。
最佳实践建议 15:经皮引流或使用塑料支架和冲洗或单独使用自膨式金属支架/腔镜贴合金属支架进行内镜经壁引流,然后进行直接内镜坏死切除术,最后进行外科清创术的阶梯式方法是合理的,尽管根据可用的临床专业知识,方法可能有所不同。